No conflicts of interest were declared.
Complete genomic landscape of a recurring sporadic parathyroid carcinoma
Article first published online: 7 JUN 2013
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 230, Issue 3, pages 249–260, July 2013
How to Cite
Kasaian, K., Wiseman, S. M., Thiessen, N., Mungall, K. L., Corbett, R. D., Qian, J. Q., Nip, K. M., He, A., Tse, K., Chuah, E., Varhol, R. J., Pandoh, P., McDonald, H., Zeng, T., Tam, A., Schein, J., Birol, I., Mungall, A. J., Moore, R. A., Zhao, Y., Hirst, M., Marra, M. A., Walker, B. A. and Jones, S. J. (2013), Complete genomic landscape of a recurring sporadic parathyroid carcinoma. J. Pathol., 230: 249–260. doi: 10.1002/path.4203
- Issue published online: 7 JUN 2013
- Article first published online: 7 JUN 2013
- Accepted manuscript online: 24 APR 2013 12:49PM EST
- Manuscript Accepted: 16 APR 2013
- Manuscript Revised: 14 APR 2013
- Manuscript Received: 15 MAR 2013
- parathyroid carcinoma;
- next-generation sequencing;
- whole genome shotgun sequencing (DNA-seq);
- whole transcriptome shotgun sequencing (RNA-seq);
- novel somatic variants;
- de novo assembly;
- expression analysis;
- data integration;
- pathway analysis
Parathyroid carcinoma is a rare endocrine malignancy with an estimated incidence of less than 1 per million population. Excessive secretion of parathyroid hormone, extremely high serum calcium level, and the deleterious effects of hypercalcaemia are the clinical manifestations of the disease. Up to 60% of patients develop multiple disease recurrences and although long-term survival is possible with palliative surgery, permanent remission is rarely achieved. Molecular drivers of sporadic parathyroid carcinoma have remained largely unknown. Previous studies, mostly based on familial cases of the disease, suggested potential roles for the tumour suppressor MEN1 and proto-oncogene RET in benign parathyroid tumourigenesis, while the tumour suppressor HRPT2 and proto-oncogene CCND1 may also act as drivers in parathyroid cancer. Here, we report the complete genomic analysis of a sporadic and recurring parathyroid carcinoma. Mutational landscapes of the primary and recurrent tumour specimens were analysed using high-throughput sequencing technologies. Such molecular profiling allowed for identification of somatic mutations never previously identified in this malignancy. These included single nucleotide point mutations in well-characterized cancer genes such as mTOR, MLL2, CDKN2C, and PIK3CA. Comparison of acquired mutations in patient-matched primary and recurrent tumours revealed loss of PIK3CA activating mutation during the evolution of the tumour from the primary to the recurrence. Structural variations leading to gene fusions and regions of copy loss and gain were identified at a single-base resolution. Loss of the short arm of chromosome 1, along with somatic missense and truncating mutations in CDKN2C and THRAP3, respectively, provides new evidence for the potential role of these genes as tumour suppressors in parathyroid cancer. The key somatic mutations identified in this study can serve as novel diagnostic markers as well as therapeutic targets. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.